Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felicitas Hitz

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Blood|September 22, 2018
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myelomaChristoph Driessen, Rouven Müller, Urban Novak, et al.
Cancer Genetics and Cytogenetics|July 5, 2005
Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published casesValérie Beyer, Dominique Mühlematter, Valérie Parlier, et al.
Haematologica|December 15, 2015
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)Christoph Driessen, Marianne Kraus, Markus Joerger, et al.
Clinical Lung Cancer|June 25, 2025
Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter StudyKira-Lee Koster, Sarvaganthasenay Yohasenan, Ahmet Samil Pakmak, et al.
Haematologica|February 9, 2012
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphomaChristoph Renner, Pier Luigi Zinzani, Rémy Gressin, et al.
Swiss Medical Weekly|April 5, 2024
Historic characteristics and mortality of patients in the Swiss Amyloidosis RegistrySofie Brouwers, Raphael Heimgartner, Natallia Laptseva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2015
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03Christian Taverna, Giovanni Martinelli, Felicitas Hitz, et al.
Blood Advances|December 4, 2020
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trialAlden A Moccia, Christian Taverna, Sämi Schär, et al.
Bone Marrow Transplantation|November 4, 2018
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry studyGuido Ghilardi, Thomas Pabst, Barbara Jeker, et al.
Blood|July 22, 2021
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell ProjectRanjana H Advani, Tetiana Skrypets, Monica Civallero, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Blood|September 22, 2018
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myelomaChristoph Driessen, Rouven Müller, Urban Novak, et al.
Cancer Genetics and Cytogenetics|July 5, 2005
Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published casesValérie Beyer, Dominique Mühlematter, Valérie Parlier, et al.
Haematologica|December 15, 2015
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)Christoph Driessen, Marianne Kraus, Markus Joerger, et al.
Clinical Lung Cancer|June 25, 2025
Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter StudyKira-Lee Koster, Sarvaganthasenay Yohasenan, Ahmet Samil Pakmak, et al.
Haematologica|February 9, 2012
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphomaChristoph Renner, Pier Luigi Zinzani, Rémy Gressin, et al.
Swiss Medical Weekly|April 5, 2024
Historic characteristics and mortality of patients in the Swiss Amyloidosis RegistrySofie Brouwers, Raphael Heimgartner, Natallia Laptseva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2015
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03Christian Taverna, Giovanni Martinelli, Felicitas Hitz, et al.
Blood Advances|December 4, 2020
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trialAlden A Moccia, Christian Taverna, Sämi Schär, et al.
Bone Marrow Transplantation|November 4, 2018
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry studyGuido Ghilardi, Thomas Pabst, Barbara Jeker, et al.
Blood|July 22, 2021
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell ProjectRanjana H Advani, Tetiana Skrypets, Monica Civallero, et al.
Pageof 6